Skip to main content

Cory Kasimov

Analyst

JP Morgan

Analyst

Evercore ISI

Equibles does not estimate personal net worth.

About Cory Kasimov

Cory Kasimov is recorded as Analyst at JP Morgan and Analyst at Evercore ISI. Cory Kasimov has spoken on 4 earnings calls across 4 companies, most recently for Alnylam Pharmaceuticals, Inc. on March 31, 2025. Those appearances were for Alnylam Pharmaceuticals, Inc. (ALNY), Biogen Inc. (BIIB), Vertex Pharmaceuticals Inc (VRTX) and Emergent BioSolutions Inc. (EBS). The companies whose calls Cory Kasimov spoke on are classified in the Healthcare sector.

Cory Kasimov on recent calls

“Apologies for asking another one related to cardio transform. But assuming that does, in fact, read out positively, how do you think about the evolution of pricing as another silencer enters the picture, especially given the Part B versus Part D dynamic?”
Analyst — Evercore ISI, Alnylam Pharmaceuticals, Inc. Q1 FY2025 Earnings Call ·
“I wanted to follow-up on the Phase 3 lecanemab study and can you comment on the enrolled patient population in terms of adequate representation for underrepresented communities that may address the CMS concerns you spoke to?”
Analyst — JPMorgan, Biogen Inc. Q4 FY2021 Earnings Call ·
“Now that the Phase II VX-864 study has initiated, are there any key differences between this and the VX-814 study that's ongoing on ClinicalTrials.gov? It looks like VX-864 is 40 patients versus 50 patients for VX-814.”
Analyst — JP Morgan, Vertex Pharmaceuticals Inc / Ma Q2 FY2020 Earnings Call ·
“Actually I have two product-related questions for you and then one big picture one. On the product-related question first and I apologize if this has been addressed but I jumped on a couple of minutes late.”
Analyst — JP Morgan, Emergent BioSolutions Inc. Q3 FY2009 Earnings Call ·

Affiliation history

  • JP Morgan

    Analyst

    Source not stated

    Current
  • Evercore ISI

    Analyst

    Source not stated

    Current

Company network

Recent activity